Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.

All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.